{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:48:27Z","timestamp":1791971307494,"version":"4.3.4"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Iron deficiency is common in patients with chronic heart failure. The IRONMAN trial investigated the effect of intravenous (IV) ferric derisomaltose (FDI) compared to usual care on a composite endpoint of hospitalisations for heart failure and cardiovascular death in patients with either new or established heart failure, iron deficiency, and a left ventricular ejection fraction \u226445%. This analysis explores the health economic consequences of being assigned to FDI rather than usual care from the perspective of NHS England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cost-utility model of FDI compared to usual care was developed based on individual patient-level data from the IRONMAN trial. The model included quality of life modelled on participant-completed EQ-5D-5L questionnaires, all non-elective hospitalisations and end-of-life care. The analysis was run over a one-year time horizon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Quality-adjusted life years (QALYs) were numerically greater for FDI (0.563) compared to usual care (0.547), a nominal difference of 0.016 QALYs (95% credible interval [CrI]: 0.002\u20130.032 QALYs) in favour of FDI. The incremental costs of acquiring and administering FDI were \u00a3357, which was more than offset by savings of \u00a3936 due to avoided hospitalisations and end-of-life care, resulting in savings of \u00a3580 (95% CrI: \u00a3493\u2013\u00a3678) per patient over one year, 15% less than the cost of usual care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Over a one-year time horizon, a within-trial analysis showed that administering FDI to patients with heart failure and iron deficiency was cost saving compared to usual care, driven primarily by reduced rates of hospitalisation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag261","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:49:40Z","timestamp":1791632980000},"source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of intravenous ferric derisomaltose for patients with heart failure and iron deficiency in the UK based on the IRONMAN trial results"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-7507","authenticated-orcid":false,"given":"R F","family":"Pollock","sequence":"first","affiliation":[{"name":"University of Glasgow, School of Health & Wellbeing , Glasgow ,","place":["UK"]},{"name":"Covalence Research Ltd , Harpenden ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P R","family":"Kalra","sequence":"additional","affiliation":[{"name":"Portsmouth Hospitals University NHS Trust, Department of Cardiology, and the University of Portsmouth , Portsmouth ,","place":["UK"]},{"name":"University of Glasgow, Robertson Centre for Biostatistics , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6517-8692","authenticated-orcid":false,"given":"A","family":"Al-Mohammad","sequence":"additional","affiliation":[{"name":"University of Sheffield, Division of Clinical Medicine, School of Medicine and Population Health , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F Z","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Group, Keele University , Keele ,","place":["UK"]},{"name":"Manchester University NHS Foundation Trust , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F J","family":"Graham","sequence":"additional","affiliation":[{"name":"University of Glasgow, School of Cardiovascular and Metabolic Health , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P A","family":"Kalra","sequence":"additional","affiliation":[{"name":"Donal O\u2019Donoghue Renal Research Centre, Salford Royal Hospital , Salford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Pellicori","sequence":"additional","affiliation":[{"name":"University of Glasgow, School of Cardiovascular and Metabolic Health , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Petrie","sequence":"additional","affiliation":[{"name":"University of Glasgow, School of Cardiovascular and Metabolic Health , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Squire","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre, Glenfield Hospital , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-1823","authenticated-orcid":false,"given":"I","family":"Ford","sequence":"additional","affiliation":[{"name":"University of Glasgow, Robertson Centre for Biostatistics , Glasgow ,","place":["UK"]},{"name":"University of Glasgow, School of Cardiovascular and Metabolic Health , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-7016","authenticated-orcid":false,"given":"J G F","family":"Cleland","sequence":"additional","affiliation":[{"name":"University of Glasgow, School of Cardiovascular and Metabolic Health , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,14]]},"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag261\/71929106\/xvag261.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag261\/71929106\/xvag261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:58:41Z","timestamp":1791968321000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article\/doi\/10.1093\/eschf\/xvag261\/8915873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag261","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"article-number":"xvag261"}}